A dose-dependent evaluation of PAbs-induced downregulation of HER1 and HER2 was compared to the magnitude reached by high-affinity cetuximab or trastuzumab in the NSCLC cell line H292 expressing wild-type variants of both receptors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.